Bioasis Technologies Stock Performance
| BIOAF Stock | USD 0.0004 0.00 0.00% |
BiOasis Technologies holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -5.83, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning BiOasis Technologies are expected to decrease by larger amounts. On the other hand, during market turmoil, BiOasis Technologies is expected to outperform it. Use BiOasis Technologies maximum drawdown, as well as the relationship between the rate of daily change and relative strength index , to analyze future returns on BiOasis Technologies.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in biOasis Technologies are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, BiOasis Technologies reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.7 M |
BiOasis |
BiOasis Technologies Relative Risk vs. Return Landscape
If you would invest 0.01 in biOasis Technologies on December 24, 2024 and sell it today you would earn a total of 0.03 from holding biOasis Technologies or generate 300.0% return on investment over 90 days. biOasis Technologies is currently producing 5.5556% returns and takes up 40.2724% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than BiOasis, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BiOasis Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BiOasis Technologies' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as biOasis Technologies, and traders can use it to determine the average amount a BiOasis Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1379
| Best Portfolio | Best Equity | BIOAF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 40.27 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.96 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average BiOasis Technologies is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BiOasis Technologies by adding it to a well-diversified portfolio.
BiOasis Technologies Fundamentals Growth
BiOasis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BiOasis Technologies, and BiOasis Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BiOasis Pink Sheet performance.
| Return On Asset | -0.81 | |||
| Operating Margin | (11.41) % | |||
| Current Valuation | 6 M | |||
| Shares Outstanding | 79.41 M | |||
| Price To Earning | 13.82 X | |||
| Price To Book | 53.47 X | |||
| Price To Sales | 26.52 X | |||
| Revenue | 37.73 K | |||
| EBITDA | (3.54 M) | |||
| Cash And Equivalents | 764.97 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 401.76 K | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (3.64 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 2.27 M | |||
| Retained Earnings | (18.69 M) | |||
| Current Asset | 874 K | |||
| Current Liabilities | 437 K | |||
About BiOasis Technologies Performance
By analyzing BiOasis Technologies' fundamental ratios, stakeholders can gain valuable insights into BiOasis Technologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BiOasis Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BiOasis Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut. Bioasis Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about biOasis Technologies performance evaluation
Checking the ongoing alerts about BiOasis Technologies for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for biOasis Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| biOasis Technologies is way too risky over 90 days horizon | |
| biOasis Technologies has some characteristics of a very speculative penny stock | |
| biOasis Technologies appears to be risky and price may revert if volatility continues | |
| biOasis Technologies has high likelihood to experience some financial distress in the next 2 years | |
| biOasis Technologies has accumulated 401.76 K in total debt with debt to equity ratio (D/E) of 0.31, which is about average as compared to similar companies. biOasis Technologies has a current ratio of 0.37, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BiOasis Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, BiOasis Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like biOasis Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BiOasis to invest in growth at high rates of return. When we think about BiOasis Technologies' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 37.73 K. Net Loss for the year was (2.96 M) with loss before overhead, payroll, taxes, and interest of (1.15 M). | |
| biOasis Technologies has accumulated about 764.97 K in cash with (3.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing BiOasis Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BiOasis Technologies' stock is overvalued or undervalued compared to its peers.
- Examining BiOasis Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BiOasis Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BiOasis Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BiOasis Technologies' pink sheet. These opinions can provide insight into BiOasis Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BiOasis Pink Sheet analysis
When running BiOasis Technologies' price analysis, check to measure BiOasis Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BiOasis Technologies is operating at the current time. Most of BiOasis Technologies' value examination focuses on studying past and present price action to predict the probability of BiOasis Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BiOasis Technologies' price. Additionally, you may evaluate how the addition of BiOasis Technologies to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |